Abstract
Topical timolol therapy is considered a relatively "safer" alternative for the treatment of infantile haemangiomas (IH); however, sufficient supportive pharmacokinetic data does not exist. Most efficacy studies have not evaluated systemic absorption.1-5 To our knowledge, this is the first prospective trial to assess the clinical response of proliferating IH to topical timolol maleate 0.5% gel-forming solution and to determine if systemic absorption occurred.Twenty-six subjects enrolled in this trial approved by the UCSD IRB.
This article is protected by copyright. All rights reserved.
http://ift.tt/2vxb7sG
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου